Venous Sinus Stenting To Treat Intractable Pulsatile Tinnitus Caused By Venous Sinus Stenosis

• Sponsor: Weill Medical College of Cornell University (Other)
• Overall Status: Terminated
• CT.gov ID: NCT02734576
• Collaborator: (none)
• Enrollment: 10
• Location: 1
• Arm: 1
• Actual Duration (Months): 37.2
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

There have been few published studies that examine the efficacy and safety of endovascular treatments on patients with pulsatile tinnitus with venous stenosis. Despite the limited experience with venous sinus stenting to treat pulsatile tinnitus, preliminary results show that venous sinus stenting could represent a viable alternative for refractory pulsatile tinnitus patients with venous sinus stenosis. The purpose of this study is to evaluate the safety and efficacy of this procedure in a controlled fashion, using strict inclusion and exclusion criteria, and long-term clinical and imaging follow-up. The investigators hope to provide robust data regarding the safety and efficacy of venous sinus stenting for patients with pulsatile tinnitus.

Condition or Disease	Intervention/Treatment	Phase
Tinnitus; Pulsatile Tinnitus; Venous Sinus Stenosis; Dural Sinus Stenosis	Device: Venous Sinus Stenting with the Precise Pro Stent	N/A

Detailed Description

WHAT IS INVOLVED IN THE STUDY?

A. Screening process - not experimental:

Patients with pulsatile tinnitus, evidence of narrowing of the large veins of the brain, and failure of prior conservative treatment will be considered for enrollment. All patients will undergo the standard of care evaluation for tinnitus by a specialist physician for diseases of the ear (Ear, Nose and Throat [ENT] physician or otorhinolaryngologist). If it is determined that the narrowing of the large veins of the brain ("dural venous sinuses") is the most likely etiology for the tinnitus, then the possibility of enrollment in the trial will be discussed. Imaging studies of the head and temporal bone will be performed in order to further confirm venous sinus stenosis as the etiology of the pulsatile tinnitus and to rule out other possible causes. Additionally, patients will answer the questions listed on the Tinnitus Handicap Inventory questionnaire.

During the screening process, investigators will review the results of tests that are not experimental and are performed as part of participants' routine care. In other words, these tests are performed regardless of participation in the study and are termed "standard procedures".

B. Participating in the study:

Participating in the trial means that the participants will undergo an experimental procedure called "venous sinus stenting" to open up the narrowing in the vein that is causing the tinnitus. This procedure requires taking two blood thinners called aspirin and Plavix. Both blood thinners will be initiated 1 week prior to the procedure and continued for 1 month after the procedure. At that time the Plavix will be stopped and aspirin will be continued for 11 more months (total of 12 months).

• Direct Retrograde Cerebral Venography (DRCV) and Manometry: A DRCV is a non-experimental procedure to look at the veins of the brain. This procedure is done by inserting a catheter (soft plastic tube) through a vein in the groin (upper leg) and guide it though the veins all the way to the neck. It is done under local anesthetic and moderate sedation. After placing the catheter in the neck, a special dye (contrast) is injected through this catheter into the veins, while X-ray cameras take multiple pictures of the veins. Then, a smaller catheter is further advanced to the area of narrowing and by this catheter investigators will measure the blood pressure at that point. This helps us to identify the severity of the narrowing. If the pressure before and after the narrowing is significantly different, then the investigators will continue with the placement of the stent in order to reopen the narrowing.

• Venous Sinus Stenting (experimental): Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. The participants will be placed under general anesthesia because it is important to not move at all during the procedure. A catheter will be inserted through the upper part of the leg (groin area) and guided through the veins all the way to neck. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed.

• Post-procedure Care: After the procedure, participants will stay in the intensive care unit for 24 hours for observation.

C. Follow-up period:

There will be no experimental procedure or test during the follow-up period. The following office visits and standard tests will be performed to evaluate the effects of the study intervention.

• Office visits: Office visits and neurological evaluation will be performed at 1, 6, 12, and 24 months after study intervention. At this time, participants will also fill the Tinnitus Handicap Inventory Questionnaire. The visits will be about 45 min.

• Audiometric assessment: An audiometric assessment will be performed at 3 months after the stenting procedure in order to assess inner ear function.

• Non-invasive imaging studies: Magnetic Resonance Venogram (MRV) is a special Magnetic Resonance Imaging (MRI) scan with injection of a dye through a vein in the arm that will allow investigators to check whether the stent is still open without new narrowing. It will be performed 12 months after the venous sinus stenting procedure. If there is clinical concern about stent patency, an expedited or intermediate MRV will be performed. If MRV is contraindicated, Computed Tomographic Venogram (CTV) will be performed instead.

D. Medications:

For the purpose of the study, the participants need to take antiplatelet drugs ("blood thinners") that are necessary to prevent formation of clot in the stent. This is a standard precaution for every stent procedure. The participants will take two drugs (called aspirin and Plavix) for 1 month and then aspirin alone for 11 more months (total time on aspirin is 12 months). It is essential that the drugs are taken every day as prescribed. As these drugs are dangerous during pregnancy, if the participant is a woman of childbearing age, then should discuss this issue with her physician, and avoid becoming pregnant during the 12 months that these drugs are needed.

Study Design

• Study Type: Interventional
• Actual Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Venous Sinus Stenting To Treat Intractable Pulsatile Tinnitus Caused By Venous Sinus Stenosis
• Actual Study Start Date: Jan 24, 2017
• Actual Primary Completion Date: Mar 1, 2020
• Actual Study Completion Date: Mar 1, 2020

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Venous Sinus Stenting Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation

Device: Venous Sinus Stenting with the Precise Pro Stent; Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).

Outcome Measures

Primary Outcome Measures

1. Number of Patients With Complete or Near-complete Resolution of Tinnitus [12 months]

   Tinnitus will be measured by: No, slight, mild, or moderate (Grades 1, 2, and 3) on Tinnitus Handicap Inventory.

2. Change in Number of Patients With Improvement of More Than One Grade in the Tinnitus Handicap Inventory Questionnaire [1, 6, 12, and 24 months after stent placement.]

   Tinnitus will be measured by: No, slight, mild, or moderate (Grades 1, 2, and 3) on Tinnitus Handicap Inventory.

Secondary Outcome Measures

1. Number of Subjects With Clinical Recurrence of Their Tinnitus [24 months]

   Clinical recurrence is if "No" tinnitus has changed back to "Slight, Mild or "Moderate."

2. Number of Subjects With Long-term Patency of the Stent [12 months]

   A subject is considered to have long-term patency if there is 100% patency of the stent at 12 months.

3. Number of Adverse Events Probably or Possibly Related to the Treatment [24 months]

4. Number of Severe Adverse Events Probably or Possibly Related to the Treatment [24 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Severe or catastrophic venous pulsatile tinnitus defined as Grades 4 or 5 on Tinnitus Handicap Inventory

• 50% or more stenosis of the lateral venous sinus on Magnetic Resonance Venogram (MRV) or Computed Tomographic Venogram (CTV_, ipsilateral to the side of more severe tinnitus

• Failure of conservative or non-surgical therapies (including sound therapy, sound masking, hearing aids, tinnitus retraining (desensitization) therapy. Failure is defined as Grades 4 or 5 on the Tinnitus Handicap Inventory despite prior treatments that have lasted for at least 3 months.

Exclusion Criteria:

• Non-pulsatile tinnitus

• Contra-indication to iodinated contrast

• Contra-indication to antiplatelet therapy

• Contra-indication to general anesthesia

• Pregnancy or plans for immediate pregnancy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	New York Presbyterian Hospital/ Weill Cornell Medicine	New York	New York	United States	10065

Sponsors and Collaborators

• Weill Medical College of Cornell University

Investigators

• Principal Investigator: Athos Patsalides, MD MPH, Weill Medical College of Cornell University

Study Documents (Full-Text)

• Study Protocol - May 12, 2017

More Information

Publications

None provided.

• Responsible Party: Weill Medical College of Cornell University
• ClinicalTrials.gov Identifier: NCT02734576
• Other Study ID Numbers: 1508016520
• First Posted: Apr 12, 2016
• Last Update Posted: Apr 2, 2021
• Last Verified: Apr 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Keywords provided by Weill Medical College of Cornell University: Venous Sinus Stenting; Dural Sinus Stenting
• Additional relevant MeSH terms: Tinnitus; Constriction, Pathologic

Study Results

Participant Flow

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Period Title: Overall Study
STARTED	10
COMPLETED	10
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Overall Participants	10
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	10 100%
>=65 years	0 0%
Sex: Female, Male (Count of Participants)
Female	9 90%
Male	1 10%
Race and Ethnicity Not Collected (Count of Participants)
Region of Enrollment (participants) [Number]
United States	10 100%

Outcome Measures

1. Primary Outcome

Title	Number of Patients With Complete or Near-complete Resolution of Tinnitus
Description	Tinnitus will be measured by: No, slight, mild, or moderate (Grades 1, 2, and 3) on Tinnitus Handicap Inventory.
Time Frame	12 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Measure Participants	10
Count of Participants [Participants]	10 100%

2. Primary Outcome

Title	Change in Number of Patients With Improvement of More Than One Grade in the Tinnitus Handicap Inventory Questionnaire
Description	Tinnitus will be measured by: No, slight, mild, or moderate (Grades 1, 2, and 3) on Tinnitus Handicap Inventory.
Time Frame	1, 6, 12, and 24 months after stent placement.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Measure Participants	10
Count of Participants [Participants]	10 100%

3. Secondary Outcome

Title	Number of Subjects With Clinical Recurrence of Their Tinnitus
Description	Clinical recurrence is if "No" tinnitus has changed back to "Slight, Mild or "Moderate."
Time Frame	24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Measure Participants	10
Count of Participants [Participants]	0 0%

4. Secondary Outcome

Title	Number of Subjects With Long-term Patency of the Stent
Description	A subject is considered to have long-term patency if there is 100% patency of the stent at 12 months.
Time Frame	12 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Measure Participants	10
Count of Participants [Participants]	10 100%

5. Secondary Outcome

Title	Number of Adverse Events Probably or Possibly Related to the Treatment
Time Frame	24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Measure Participants	10
Number [adverse events]	0

6. Secondary Outcome

Title	Number of Severe Adverse Events Probably or Possibly Related to the Treatment
Time Frame	24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
Measure Participants	10
Number [severe adverse events]	0

Adverse Events

Time Frame	24 months
Adverse Event Reporting Description	Any cause of disability.
Arm/Group Title	Venous Sinus Stenting
Arm/Group Description	Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain.
All Cause Mortality
	Venous Sinus Stenting
	Affected / at Risk (%)	# Events
Total	0/10 (0%)
Serious Adverse Events
	Venous Sinus Stenting
	Affected / at Risk (%)	# Events
Total	0/10 (0%)
Other (Not Including Serious) Adverse Events
	Venous Sinus Stenting
	Affected / at Risk (%)	# Events
Total	0/10 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.